These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25694309)

  • 41. Strategies for conducting intervention research in schools.
    Frauman AC; Criswell ES; Harrell JS
    West J Nurs Res; 1998 Apr; 20(2):242-50. PubMed ID: 9550935
    [No Abstract]   [Full Text] [Related]  

  • 42. Doubly randomized delayed-start design for enrichment studies with responders or nonresponders.
    Liu Q; Lim P; Singh J; Lewin D; Schwab B; Kent J
    J Biopharm Stat; 2012; 22(4):737-57. PubMed ID: 22651112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How do we know what we know? The randomized controlled trial revisited.
    Heaney RP
    J Bone Miner Res; 1991 Feb; 6(2):103-5. PubMed ID: 2028831
    [No Abstract]   [Full Text] [Related]  

  • 44. Design and statistical issues in multicenter trials of severe head injury.
    Choi SC; Bullock R
    Neurol Res; 2001; 23(2-3):190-2. PubMed ID: 11320598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low patient enrollment sites in multicenter randomized clinical trials of cerebrovascular diseases: associated factors and impact on trial outcomes.
    Qureshi AI; Tariq N; Vazquez G; Novitzke J; Suri MF; Lakshminarayan K; Haines SJ
    J Stroke Cerebrovasc Dis; 2012 Feb; 21(2):131-42. PubMed ID: 20719541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
    Emery S; Abrams DI; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD;
    Control Clin Trials; 2002 Apr; 23(2):198-220. PubMed ID: 11943448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The use and pitfalls of large randomized controlled trials].
    Tang JL; Yang ZY; Mao C
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Oct; 38(10):1299-1304. PubMed ID: 29060968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study.
    Carter RE; Sonne SC; Brady KT
    BMC Med Res Methodol; 2005 Mar; 5():11. PubMed ID: 15796782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Block randomization in clinical trials].
    Yang HL; Wu XB; Mao C
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Apr; 53(4):437-440. PubMed ID: 30982284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blinding in pharmaceutical clinical trials: An overview of points to consider.
    Crisp A
    Contemp Clin Trials; 2015 Jul; 43():155-63. PubMed ID: 26044462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?
    Li G; Sajobi TT; Menon BK; Korngut L; Lowerison M; James M; Wilton SB; Williamson T; Gill S; Drogos LL; Smith EE; Vohra S; Hill MD; Thabane L;
    J Clin Epidemiol; 2016 Dec; 80():16-24. PubMed ID: 27555082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized controlled trials 6: On contamination and estimating the actual treatment effect.
    Parfrey PS
    Methods Mol Biol; 2015; 1281():249-59. PubMed ID: 25694314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cluster-randomized trials.
    Fayers PM; Jordhøy MS; Kaasa S
    Palliat Med; 2002 Jan; 16(1):69-70. PubMed ID: 11963457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lessons learned from benchmark orthopaedic trials.
    Swiontkowski MF; Agel J
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():11-4. PubMed ID: 22810440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of the data coordinating center in the DIG trial.
    Williford WO; Collins JF; Horney A; Kirk G; McSherry F; Spence E; Stinnett S; Howell CL; Garg R; Egan D; Yusuf S;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):277S-288S. PubMed ID: 14643074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revisiting sample size: are big trials the answer?
    Lurati Buse GA; Botto F; Devereaux PJ
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():75-9. PubMed ID: 22810453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved Designs for Cluster Randomized Trials.
    Crespi CM
    Annu Rev Public Health; 2016; 37():1-16. PubMed ID: 26789386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bias control in clinical trials: masking or blinding.
    Galvez-Olortegui JK; Gonzales-Saldaña J; Garcia-Gomez I; Silva-Ocas I; Gutierrez-Arana J; Galvez-Olortegui T; Condor-Rojas YC
    Medwave; 2015 Dec; 15(11):e6349. PubMed ID: 26731671
    [No Abstract]   [Full Text] [Related]  

  • 60. New developments in the conduct and management of multi-center trials: an international review of clinical trial units.
    Gluud C; Sørensen TI
    Fundam Clin Pharmacol; 1995; 9(3):284-9. PubMed ID: 7557825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.